Soumya Raychaudhuri, PhD
Internal Medicine · Boston, MANPI 1376659144
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $146,586 of the $167,485 with a category attached, or 87.5%. 11 manufacturers reported payments, led by Pfizer at 31.9% of the total. Among internal medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 82 payments — averaging $2042.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$53K
- Janssen Research & Development, LLC$28K
- Gilead$22K
- E.r. Squibb & Sons, L.L.C.$15K
- Sanofi US Services Inc.$14K
- Merck$13K
- plus $22K from 5 others
Across 6 payments — averaging $167,883 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$570K
- Pfizer$438K
What the payments were for
- Consulting fees$146,58688%
- Speaking & faculty fees$11,0007%
- Travel & lodging$8,2065%
- Food & beverage$1,6931%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 17 | $53,463 |
| Janssen Research & Development, LLC | 18 | $28,244 |
| Gilead | 10 | $22,421 |
| E.r. Squibb & Sons, L.L.C. | 7 | $14,967 |
| Sanofi US Services Inc. | 2 | $13,863 |
| Merck | 11 | $12,967 |
| AbbVie | 6 | $10,146 |
| Bristol Myers Squibb | 1 | $4,890 |
| Biogen | 2 | $3,834 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $2,500 |
| GSK | 7 | $191 |
How this compares
$167,485 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 24 | $168,008 |
| Leucovorin Calcium | 15 | $6,686 |
| MethotrexateMethotrexate Sodium | 42 | $1,779 |
| Meloxicam | 19 | $43 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Boston
- David SchenkeinBoston$5M
- John FallonBoston$1.8M
- Michael MendelsohnBoston$1.6M
- Gaurav SingalBoston$798K
- Asit ParikhBoston$486K
- Noopur RajeBoston$481K
- Daniel KuritzkesBoston$443K
- Xiuning leBoston$364K
- Nancy GaglianoBoston$358K
- Fatima StanfordBoston$285K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.